Biohaven stock slides on withdrawal of European marketing application

Biohaven stock drops after pulling EU application (BHVN:NYSE)

Biohaven (NYSE:BHVN) stock falls as the company withdraws EU application for rare disease therapy Dazluma to collect more data. Read more here.

Biohaven stock slides on withdrawal of European marketing application

The drug, being developed for a rare genetic disorder and currently under review in the U.S., is seen by some investors as critical to Biohaven’s future.

Biohaven share price undervaluing pipeline potential, says RBC Capital

In This Article: RBC Capital points out that notes released by the European Medicines Agency’s CHMP indicated that Biohaven (BHVN) had withdrawn the application for troriluzole in spinocerebellar ataxia. Investor sentiment has been more bearish lately, with most believing that SCA approval in the…

Biohaven stock slides on withdrawal of European marketing application - EUROPE SAYS

Biohaven lost close to $400 million in market value Friday on news that the Connecticut-based drug developer had withdrawn an application to get one of its

Biohaven Stock Slides On Withdrawal Of European Marketing Application - Data Intelligence

Biohaven lost close to $400 million in market value Friday on news that the Connecticut-based drug developer had withdrawn an application to get one of its most advanced experimental therapies approved in Europe. The company first asked the European Medicines Agency for approval in late 2023, believing enough evidence had been gathered to show its drug, tentatively branded as Dazluma, is effective at treating “spinocerebellar ataxia,” a type of …